CapsoVision Inc

CV

Market cap $259M

Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ET Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ET

- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced that the company will release second quarter 2025 financial results on Thursday, August 14, 2025, after the close of market.

SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares began trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.”

SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.” The offering is expected to close on July 3, 2025 subject to the satisfaction of customary closing conditions.

Four IPOs and five SPACs debuted this week. Four IPOs and two SPACs submitted initial filings this week. The July IPO market is slated for a quiet start, with just a couple IPOs scheduled for the short Fourth of July week ahead.

CapsoVision, Inc. is seeking $27.6M in an IPO, but faces slowing revenue growth, high losses, and minimal operating capital. CapsoVision's valuation expectations are excessive, with an 18x EV/Revenue multiple versus industry norms, despite flattening topline growth. Financials show rising operating losses, negative free cash flow, and declining marketing efficiency, raising concerns about sustainability.